Introduction
Recombinant viral vectors have proven successful in the transfer and expression of foreign genes in vivo. [1] [2] [3] [4] Vectors based on adeno-associated virus (AAV) hold particular promise for both gene therapy and neurobiological research since AAV is a defective virus that integrates into the human genome, 5 yet produces no known pathology. 6 Recombinant AAV (rAAV) vectors have been shown to transfer and express genes that reverse neurological deficits 2 or alter endogenous neurotransmitter receptor function. 7 A primary distinction between AAV and other vectors is that long-term gene expression (over 1 year) 8 is achievable without signs of toxicity or significant immune response. 2, 9 Recently, the production of high-titer rAAV in the absence of helper virus 10 has facilitated the use of the rAAV vector system as a powerful neurobiological tool and a potential gene therapy drug. However, for any of these applications an important component is the ability to control the vector transgene expression in vivo.
In mammalian cells, both the tetracycline-responsive system 11 and the ecdysone-inducible system 12 have proven effective in regulating exogenous gene expression. Recently, RU486 has been demonstrated to induce the expression of a transgene in vivo 13 thus expanding the number of regulated systems now available. For in vivo gene transfer applications, the tetracycline-responsive system contains a number of advantages for regulating rAAV gene expression. Since AAV vectors have a cassette limit of 4.5 kb, the small size of the tetracycline-responsive cis elements and repressor (2.1 kb) allows for the inclusion of many therapeutic genes. Second, gene expression from the tetracycline-responsive promoter is dose-responsive, 11 and tetracycline as well as many of its derivatives cross the blood-brain barrier, a feature required for regulation in the brain. Finally, this system has been shown to regulate gene expression in vivo using transgenic mouse models, 14, 15 somatic transfer via herpes simplex virus (HSV) amplicon vectors 16 and adenoviral vectors. 17 In the case of HSV transfer, however, rapid decline in gene expression prevented a thorough testing of gene inducibility. 16 Since long-term stable in vivo gene expression can be obtained with AAV vectors, 9 the studies presented here sought to ascertain if a rAAV vector carrying a regulated gene expression system would function both in vitro and in vivo. An AAV dual cassette vector carrying the tetracycline-responsive system was tested for regulated gene expression after transduction on tissue culture cells or direct injection into rat brain. The outcome of these studies demonstrate regulated gene expression from the AAV vector by the presence or absence of drug in the media of cells or drinking water of test animals. These results strongly support this vector system for long-term regulated gene expression within the brain, and may have significant use in clinical settings that require control of the therapeutic transgene after vector delivery.
Results

Construction of viral vectors
A dual cassette AAV vector plasmid, pGFPtTAk, was constructed where the coding sequences for enhanced green fluorescent protein (GFP) were under the transcriptional control of the tetracycline-responsive promoter. This promoter contains a CMV minimal promoter and seven copies of the tetO sequence (see Figure 1a) . 11 The gene for a modified tetracycline transactivator (tTAk), 18 which binds tetO, was included in the same construct. Because the tTAk gene was also under the control of the tetracycline-responsive promoter, transcriptional control existed for both the GFP and tTAk genes, minimizing leaky transcription and possible cytotoxic effects of the tTAk protein. High expression levels of both genes in this cassette depend upon the activity of the minimal CMV promoter to express a small amount of tTAk protein, which can initiate a feed-forward loop to enhance the transcription of both tTAk and GFP (Figure 1b) . Tetracycline decreases expression by complexing with tTAk and preventing it from binding to tetO. The recombinant virus, rAAV-GFPtTAk, which was derived from this plasmid carries both genes between the AAV terminal repeats. Figure 1 (a) 
Regulation of rAAV-GFPtTAk by tetracycline in vitro
In HEK 293 cells, pGFPtTAk transfection or rAAVGFPtTAk transduction exhibited tetracycline-sensitive GFP expression (data not shown). However, rapid cell proliferation and low expression did not permit investigation of tetracycline responsiveness over time. Therefore, stable cell lines were isolated by infecting HeLa cells with rAAV-GFPtTAk. Five cell lines were isolated by limiting dilution cloning (HGtTA 1-30, 4-12, 6-41, 8-13 and 8-31) and were maintained in the absence of tetracycline. Each cell line retained fluorescence for over 20 passages with no decrease in intensity (data not shown). In each case fluorescence decreased in the presence of tetracycline as shown in Figure 2a and c. GFP expression completely recovered after removal of tetracycline ( Figures  2d and 3b) . Quantification of whole cell extracts using a fluorescence plate reader revealed a more than 20-fold decrease in expression in response to 1 g/ml tetracycline in cell lines, HGtTA 1-30, 6-41, 8-13 and 8-31 (Figure 3a) . Fluorescence was reduced by only 2.5-fold in HGtTA 4-12, however, this isolate expressed highest initial fluorescence. The largest reduction in GFP expression obtained was 27-fold (HGtTA 1-30). Doxycycline (dox), a potent tetracycline analog, produced similar decreases in GFP (data not shown).
To ensure that tetracycline treatment was reversible, the fluorescence intensity of one cell line, HGtTA 8-13, was monitored over time during tetracycline administration and removal. Cells were treated for 9 days (three passages) with 1 g/ml tetracycline and then transferred to tetracycline-free medium for another 9 days. GFP expression reached its lowest level (3.5% of maximum) 6 days after beginning tetracycline treatment and maintained this level as long as tetracycline was maintained in the cell culture medium, (Figure 3b ). Upon tetracycline withdrawal, cell fluorescence completely recovered to pre-tetracycline levels, demonstrating that tetracycline did not permanently alter GFP expression.
rAAV-GFPtTAk controllable gene expression in the brain
To investigate gene delivery and regulation in the brain, rAAV-GFPtTAk was microinjected into the inferior colliculi (IC) of rats, a location shown to be permissive for AAV-mediated long-term gene expression. 9 Strong GFP fluorescent cells could be seen in the injected IC at 1 week after injection but not in the contralateral uninjected IC (data not shown). At 3 and 6 weeks after injection, GFP expression was equivalent to or brighter than at 1 week with no apparent reduction in the number of cells transduced (Figures 4a and 5b ). The intensity of expression and number of cells transduced by AAV-GFPtTAk was similar to a CMV-driven rAAV (data not shown). By their morphology, all transduced cells appeared to be neurons, consistent with previous reports of AAV vector transduction in the brain. To demonstrate control of gene expression, animals were administered 300 g/ml doxycycline continuously in their water beginning 2 days before virus administration until death at either 3 or 6 weeks after injection. In some animals no green cells could be found, even though successful injections were confirmed by injector tract damage (red area in Figure 4b and c). Other doxycycline-treated animals contained fewer faintly positive cells as compared with untreated controls (Figure 4b) , and longer exposure times were needed to see these cells clearly (Figure 4c ), supporting significant down-regulation of the vector-transduced gene.
To modulate gene expression off and on, two groups of animals had their doxycycline conditions switched halfway through treatment. The animal group used to turn active vector gene expression off (off dox/on dox) was given doxycycline beginning 3 weeks after microinjection of the virus and was maintained on doxycycline for the subsequent 3 weeks. Brain sections from these ani- mals showed significantly reduced GFP fluorescence, whereas control animals killed after 3 weeks with no treatment showed very strong expression (Figure 5a and c). An additional group of animals was used to show the reverse: activation of vector gene expression after removal of doxycycline. These animals (on dox/off dox) were administered doxycycline for 3 weeks after injection and then taken off the drug for the subsequent 3 weeks. Sections from these animals had many bright GFP expressing cells indicating recovery from doxycycline administration (Figure 5b and d) . Control animals killed after 3 weeks of doxycycline treatment demonstrated very little GFP fluorescence, as expected.
Counts of the positive cells were initially performed to quantify the effect of doxycycline on gene expression and, in general, there were fewer cells in the doxycyclinetreated animals than in those without treatment. However, variability in animal to animal injections made these numbers statistically nonsignificant. Therefore, differences in gene expression were further quantified by com- Table 1 gives the average cell fluorescence for each group of animals. Consistent with visual inspection, the average cell fluorescence in doxycycline-treated animals was considerably lower (6.5%) than that of untreated animals. The animal group used to turn active vector gene expression off demonstrated as much repression of GFP fluorescence as the a No dox animals did not receive any doxycycline for the entire period after injection until death. b Dox animals were administered doxycycline in their water for the entire period after injection until death. c Off dox/on dox animals were administered water without doxycycline for 3 weeks after injection and then given doxycycline in water for the last 3 weeks until death. d On dox/off dox animals were administered doxycycline in their water for 3 weeks after injection and then given no doxycycline for the last 3 weeks until death.
animals that were given doxycycline for 6 weeks continuously. In addition, the group of animals used to activate vector gene expression after down-regulation showed significant recovery of fluorescence nearly to the level of untreated animals (Table 1 , Figure 5b and d) . Although the doxycycline dose of 300 g/ml repressed gene expression to a large extent, some leaky GFP expression could still be seen. In the event that inadequate amounts of doxycycline reached the brain, the above experiments were repeated with a 2 mg/ml dose of doxycycline. As shown in Table 1 , no further repression was achieved by the increased doxycycline dose, suggesting maximum levels were obtained with the concentration initially used in these studies.
Discussion
These studies demonstrate that recombinant AAV can transfer a controllable gene expression cassette and produce stable, regulatable gene expression both in vitro and in vivo. In vitro, AAV-transduced HeLa cells exhibited tetracycline-sensitive gene expression for more than 20 passages, while in vivo, tetracycline-sensitive gene expression was maintained for at least 6 weeks in the inferior colliculus (duration of the experiment). Thus, following AAV gene transfer, in vivo expression of foreign genes can be regulated for long periods of time. These studies are significant when compared with other delivery systems that have been hampered due to problems with stable gene expression after transfer of the tetracycline controllable system to neurons. For example, herpes simplex virus amplicon vectors have been used to package the tetracycline-responsive system and confer transcriptional regulation on transduced genes. 16, 19 These vectors can stably transduce dividing cells in vitro, however, regulation in these studies lasted for only a short time period in the brain, about 2-6 days. 19 Adenovirus vectors containing the tetracycline-responsive system have recently demonstrated lengthy regulation in the brain as well as in primary neuronal cultures. 17, 20 As these studies provided no quantification, the extent of control with these vectors is unclear. In the past, however, stability of expression and immune reactions in vivo have impacted efficient use of the adenoviral system. 21 The present studies show that the tetracycline-responsive AAV vector can confer expression and extensive regulation for at least 6 weeks in vivo. In addition, AAV vectors have been demonstrated to transduce cells in the brain for over a year. 8 This observation, when related to the present studies where no decrease in intensity or cell number was apparent over 6 weeks, strongly supports the fact that tetracycline-responsiveness will persist as long as the vector.
Although considerable regulation in gene expression could be obtained between the on and off states with this AAV vector, some residual gene expression remained in the off state, both in vitro and in vivo. Since retroviral vector studies have demonstrated a 300-fold tetracycline sensitive decrease in gene expression in stable cell lines, 22 it is not likely that all the residual expression accrues from the minimal promoter in the tetracycline-responsive system. Similarly, animals exhibited some low intensity green cells, even with doxycycline doses of 2 mg/ml, in contrast to transgenic mouse models where the tetracycline-responsive system produced nearly complete repression of a luciferase reporter gene in peripheral tissues. 23 One possible explanation for this residual activity is the minimal CMV promoter in the tetracyclineresponsive system. However, an influence of the viral vector upon the minimal promoter cassette may also be at play here. For example, some evidence exists that the AAV terminal repeats have transcriptional activity, as either a promoter or an enhancer. 24, 25 Support of this analogy is that recombinant vectors constructed from another parvovirus, LuIII, resulted in terminal repeat enhancement of basal gene expression from the tetracycline-responsive promoter. 26 If this residual gene expression is due to terminal repeat influence on the CMV minimal promoter, it may be necessary to design AAV vectors that achieve greater gene repression during doxycycline exposure, or switch to other regulated systems. A recent report using HSV and RU486 regulation demonstrated successfully controlled gene expression both in vitro and in vivo. 13 Forty-eight hours after vector delivery, a 150-fold difference in gene expression could be demonstrated in vivo illustrating significant advantages of different regulation systems. From this study it is clear that AAV vectors can carry dual gene cassettes that confer regulated gene expression for extended periods of time.
A vector that can deliver long-term, controllable gene expression, such as the one described here, has numerous applications in the field of gene therapy. Not only will such control allow greater insight into gene product function in brain, such as growth factors, but it may be particularly important for the application of gene therapy to neurological disorders such as Parkinson's disease. Based on these findings, future studies using AAV vectors with therapeutic genes should meet with success when assayed for on/off regulation over prolonged periods of time.
Materials and methods
Construction of pGFPtTAk
The 490 bp XbaI-XhoI fragment from pUHD10-3 (Life Technologies, Gaithersburg, MD, USA) containing the tetracycline-responsive promoter was cloned in place of the CMV promoter of the AAV plasmid P BS TRUF2 (a kind gift from N Muzyczka, University of Florida, Gainesville, FL, USA). The SalI fragment of the resulting vector was replaced with the 1546 bp XhoI-SpeI fragment of pTET-tTAk (Life Technologies) that contained the tTAk gene driven by the tetracycline-responsive promoter. Finally, the GFP gene was replaced with enhanced GFP from pEGFP-N1 (Clontech, PaloAlto, CA, USA) (see Figure 1a) .
Virus production
Recombinant AAV was made as previously described 27 by the UNC vector core facility. Briefly, 293 cells were transfected with pGFPtTAK and pAAV/AD by the calcium phosphate method. Five to 7 h later cells were infected with adenovirus and allowed to incubate for another 48-60 h. Alternatively, cells were transfected with pGFPtTAk, pAAV/AD and XX6 28 and incubated for 48-72 h. Cells were then collected, lysed by three freezethaw cycles, and centrifuged to pellet out debris. AAVGFPtTAk was further purified over two cesium chloride gradients and dialyzed against PBS. Before use, AAV made with adenovirus was heated to 65°C for 30 min to inactivate any remaining adenovirus. Purified AAVGFPtTAk was 2.8 × 10 8 to 1.8 × 10 9 transducing units (TU) per ml, as titrated on HtTA-1 cells.
HGtTA cell lines
HeLa cells at a concentration of 2.5 × 10 5 cells per well in six-well plates were infected with 10 TU per cell of cesium gradient purified AAV-GFPtTAk in DMEM plus 10% fetal calf serum. The medium was changed after 24 h and cells were maintained in DMEM plus 10% FCS throughout the experiment. Infected cells were passaged three times and then diluted into 96-well plates at 100 cells per well. Green colonies were allowed to reach confluence in 48-well plates and diluted a second time to one to two cells per well in 96-well plates. After 2-3 weeks, single colonies of green cells were grown to confluence and used for experiments. Two cell lines, HGtTA 6-41 and HGtTA 8-13, were diluted a second time to one to two cells per well in 96-well plates to ensure single cell clones. Cell lines were maintained in the absence of tetracycline. For experiments, tetracycline was administered at a final concentration of 1 g/ml that was diluted from a 1 mg/ml stock dissolved in 100% ethanol. Control plates were given an equivalent amount of ethanol or left untreated. Doxycycline was also dissolved in ethanol and diluted to a final concentration of 0.5 g/ml.
Quantitative fluorescence Whole cell extracts were made from confluent plates of cells by incubating for 1 h at 4°C in lysis buffer (50 mm Tris, pH 8.0, 150 mm NaCl, 0.5% NP40, 50 mm NaF). Lysates were cleared by centrifugation and stored at −80°C until use. The protein content of extracts was quantified by BioRad (Hercules, CA, USA) protein assay. Equivalent amounts of protein from each plate were diluted to a final volume of 100 l and read in a microtiter plate with a fluorescent plate reader. Excitation wavelength was 485 nm and emission was 530 nm.
AAV microinjection
Injections were performed as previously described. 9 Briefly, male Sprague-Dawley rats were anesthetized with pentobarbital and placed in a stereotaxic frame. A 30-gauge stainless steel tube was used to infuse the virus using coordinates from the atlas of Paxinos and Watson 29 (0.7 mm interaural, 1.7 mm lateral, 4.0 mm vertical). One or 2 l of virus was infused at a rate of 1 l/4.5 min, and the injector was allowed to remain for 1 min after infusion to allow for spread of the virus. In the first experiment rats were supplied with either 2.5% sucrose or 2.5% sucrose supplemented with 300 g/ml doxycycline as their only source of water beginning 2 days before microinjection of the virus. In the second experiment animals were given either 4% sucrose or 4% sucrose with 2 mg/ml doxycycline. The average daily intake was 40.9 ml for 300 g/ml dose (12.4 mg doxycycline per day) animals and 41.3 ml for 2 mg/ml dose (82.5 mg doxycycline per day). After 1, 3 or 6 weeks, animals were perfused with 4% phosphate-buffered paraformaldehyde and the brains allowed to fix overnight in paraformaldehyde. Inferior colliculi were sectioned at 50 m on a Leica (Heerbrugg, Switzerland) vibrating blade microtome, mounted on to glass slides and visualized with fluorescence microscopy with an FITC or an FITC/rhodamine dual pass filter.
Individual cell quantification
Fluorescence of individual cells in mounted 50 m sections were viewed with a fluorescence microscope employing a FITC filter. A black and white digital camera recorded these images. Boundaries of individual cells were hand drawn and average fluorescence intensity for each cell was determined using the ISEE Inovision (Durham, NC, USA) software. Approximately 20 cells from two to three sections per animal were quantified.
